A major scientific review has confirmed what billions of vaccine doses have demonstrated: mRNA vaccines are safe and effective, with serious adverse events occurring in only a tiny fraction of recipients. Researchers analyzing laboratory research, clinical trials, and real-world safety data found that the benefits of protection against severe disease, hospitalization, and death substantially outweigh the risks of rare complications.

What Did the Lancet Review Actually Find?

Scientists led by Dr. Anna Blakney at the University of British Columbia conducted a comprehensive analysis of mRNA vaccine evidence published between 2000 and the end of 2025. Rather than examining a single vaccine or study, they evaluated the entire mRNA platform by drawing on data from laboratory research, clinical trials, and real-world surveillance of billions of doses administered worldwide.

The findings were reassuring. Serious adverse events were rare and well-characterized, consistently outweighed by substantial protection against severe disease, hospitalization, and death. For example, myocarditis and pericarditis, which are types of heart inflammation, occurred at rates of roughly 12.6 cases per million doses for Pfizer-BioNTech's vaccine and about 35.6 cases per million for Moderna's vaccine. Importantly, the risk of these complications was significantly lower than the risk of developing the same conditions after catching COVID-19 itself.

Other serious adverse events were also very rare. Anaphylaxis, a severe allergic reaction, occurred in only 4.7 cases per million doses of the Pfizer-BioNTech vaccine. Most other side effects, such as sore arms, fatigue, or fever, were mild to moderate and resolved within a few days.

How Do mRNA Vaccines Work, and Why Are They Safe?

Understanding how mRNA vaccines function helps explain why they have such a favorable safety profile. These vaccines work by delivering genetic instructions that enable the body's own cells to temporarily produce a target protein, such as the spike protein found on the surface of SARS-CoV-2. This trains the immune system to recognize and attack the protein and any pathogens carrying it.

The Lancet review examined several questions that have fueled debate about mRNA vaccines since their widespread deployment during the COVID-19 pandemic. Researchers found that both the mRNA and lipid nanoparticles injected into the body are temporary, remaining largely at the injection site and nearby lymph nodes before being broken down. Critically, mRNA does not enter the cell nucleus where DNA is stored, and the vaccine-produced protein is expressed only briefly before being cleared from the body. These characteristics underpin the platform's favorable safety profile.

What's Next for mRNA Technology Beyond COVID?

The review highlights that mRNA vaccines have potential far beyond COVID-19. Researchers are exploring applications in several areas:

• Infectious Disease Prevention: Vaccines against influenza, RSV (respiratory syncytial virus), and other emerging infectious diseases are in development or clinical trials.
• Cancer Treatment: Personalized cancer vaccines that train the immune system to target tumor cells are being investigated as a potential therapeutic approach.
• Other RNA-Based Therapies: The platform may enable treatment of various health conditions beyond infectious disease and cancer.

Dr. Manish Sadarangani of the University of British Columbia and BC Children's Hospital Research Institute emphasized the broader significance of these findings. "mRNA vaccines have already transformed how we respond to emerging diseases, and with ongoing innovation and rigorous safety monitoring, they can drive progress in preventive medicine and cancer treatment for years to come," he stated.

"Across billions of administered doses, serious adverse events have been rare, well characterised, and consistently outweighed by the substantial protection conferred against severe disease, hospitalisation, and death," said Dr. Anna Blakney and colleagues.

Dr. Anna Blakney, University of British Columbia

What Do Experts Say About Future Safety Monitoring?

While the evidence is reassuring, researchers emphasize that ongoing vigilance remains important. The authors of the Lancet review called for continued safety monitoring and long-term follow-up of rare adverse events, as well as clear and proactive communication with the public about vaccine safety.

They also stressed the need for greater investment in manufacturing and technology transfer to ensure that future mRNA technologies are accessible globally, not just in wealthy nations. As the world continues to confront evolving infectious threats, sustained innovation, robust surveillance, and true global collaboration will be essential to maximize the life-saving benefits of this groundbreaking technology.

The comprehensive review provides strong reassurance for people considering mRNA vaccines and underscores the scientific foundation supporting their use in protecting public health for years to come.